Trial Profile
Xenogeneic HER2/Neu DNA immunization for patients with metastatic and high risk breast cancer: a phase I study to assess safety and immunogenicity
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 07 Jun 2023
Price :
$35
*
At a glance
- Drugs Trastuzumab (Primary)
- Indications Advanced breast cancer
- Focus Adverse reactions; Pharmacogenomic
- 01 Jun 2023 Planned End Date changed from 1 May 2023 to 1 May 2025.
- 01 Jun 2023 Planned primary completion date changed from 1 May 2023 to 1 May 2025.
- 01 Jun 2022 Planned End Date changed from 1 May 2022 to 1 May 2023.